Immune Design Overview
- Year Founded
-
2008
- Status
-
Acquired/Merged
- Employees
-
50
- Latest Deal Type
-
M&A
- Financing Rounds
-
8
Immune Design General Information
Description
Immune Design is a clinical-stage immunotherapy company. Its focus is next-generation in vivo methods intended to enable the body's immune system to fight diseases. The company's therapies have a broad potential approach across multiple therapeutic areas. Nevertheless, the company's target is oncology, and it is developing tumor-specific cytotoxic T cells to fight cancer. The main discoveries are CMB305 and G100, immuno-oncology approaches that are believed to address the shortcomings of existing oncological therapies.
Contact Information
Website
www.immunedesign.comCorporate Office
- 1616 Eastlake Avenue East
- Suite 310
- Seattle, WA 98102
- United States
Corporate Office
- 1616 Eastlake Avenue East
- Suite 310
- Seattle, WA 98102
- United States
Immune Design Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Immune Design Comparisons
Industry
Financing
Details
Immune Design Competitors (63)
One of Immune Design’s 63 competitors is Lexeo Therapeutics, a Formerly VC-backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lexeo Therapeutics | Formerly VC-backed | New York, NY | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Xenetic Biosciences | Corporation | Framingham, MA | ||||
| ImCheck Therapeutics | Formerly VC-backed | Marseille, France | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA |
Immune Design Patents
Immune Design Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3897700-A1 | Pathogen-associated molecular pattern molecules and rna immunogenic compositions and methods of using the compositions for treating cancer | Inactive | 17-Dec-2018 | ||
| EP-3897700-A4 | Pathogen-associated molecular pattern molecules and rna immunogenic compositions and methods of using the compositions for treating cancer | Inactive | 17-Dec-2018 | ||
| US-20220054611-A1 | Pathogen-associated molecular pattern molecules and rna immunogenic compositions and methods of using the compositions for treating cancer | Inactive | 17-Dec-2018 | ||
| WO-2020131656-A1 | Pathogen-associated molecular pattern molecules and rna immunogenic compositions and methods of using the compositions for treating cancer | Inactive | 17-Dec-2018 | ||
| WO-2018148180-A2 | Materials and methods for identifying and treating cancer patients | Inactive | 07-Feb-2017 | G01N33/6854 |
Immune Design Signals
Immune Design Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Immune Design FAQs
-
When was Immune Design founded?
Immune Design was founded in 2008.
-
Where is Immune Design headquartered?
Immune Design is headquartered in Seattle, WA.
-
What is the size of Immune Design?
Immune Design has 50 total employees.
-
What industry is Immune Design in?
Immune Design’s primary industry is Drug Discovery.
-
Is Immune Design a private or public company?
Immune Design is a Private company.
-
What is the current valuation of Immune Design?
The current valuation of Immune Design is .
-
What is Immune Design’s current revenue?
The current revenue for Immune Design is .
-
How much funding has Immune Design raised over time?
Immune Design has raised $130M.
-
Who are Immune Design’s investors?
Alta Partners, Altamont Pharmaceutical Holdings, Aventis, Osage University Partners, and ProQuest Investments are 5 of 9 investors who have invested in Immune Design.
-
Who are Immune Design’s competitors?
Lexeo Therapeutics, CytomX Therapeutics, Xenetic Biosciences, ImCheck Therapeutics, and Sorrento Therapeutics are some of the 63 competitors of Immune Design.
-
When was Immune Design acquired?
Immune Design was acquired on 02-Apr-2019.
-
Who acquired Immune Design?
Immune Design was acquired by Merck & Co..
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process